Core Laboratories N.V. (CLB) receives a strong valuation score of 69 from InvestorsObserver analysis. Our proprietary scoring system considers the overall health of the company by looking at the stock's price, earnings, and growth rate to determine if it represents a good value. CLB holds a better value than 69% of stocks at its current price. Investors who are focused on long-term growth through buy-and-hold investing will find the Valuation Rank especially relevant when allocating their assets.
CLB gets a 69 Valuation Rank today. Find out what this means to you and get the rest of the rankings on CLB!
CLB has a trailing twelve month Price to Earnings (PE) ratio of 35.1. The historical average of roughly 15 shows a poor value for CLB stock as investors are paying higher share prices relative to the company's earnings. CLB's high trailing PE ratio shows that the firm has been trading above its fair market value recently. Its trailing 12-month earnings per share (EPS) of 0.67 does not justify the stock's current price. However, trailing PE ratios do not factor in the company's projected growth rate, resulting in many newer firms having high PE ratios due to high growth potential enticing investors despite inadequate earnings.
CLB currently has a 12-month-forward-PE-to-Growth (PEG) ratio of 1.63. The market is currently overvaluing CLB in relation to its projected growth due to the PEG ratio being above the fair market value of 1. CLB's PEG comes from its forward price to earnings ratio being divided by its growth rate. Because PEG ratios include more fundamentals of a company's overall health with additional focus on the future, they are one of the most used valuation metrics by analysts.
